Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presendin (exenatide) in idiopathic intracranial hypertension
2021-006664-24Phase 3Terminated
- Sponsor
- Invex Therapeutics Ltd
- Start
- Dec 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic intracranial hypertension (IIH) comparing Presendin (exenatide) with Placebo (2 arms). Primary endpoint: Change in intracranial pressure. Started Dec 2022; status: terminated.
02
Drugs
Presendin
03
Conditions
idiopathic intracranial hypertension (IIH)
Beyond the preview
Go deeper on 2021-006664-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006664-24.